



Budget 2023-24

This information is accurate as of 9 May 2023.

National Immunisation Program

This measure will:

- add the Shingrix vaccine to the National Immunisation Program (NIP) as a standard vaccine. This vaccine will be an alternative to the herpes zoster vaccine Zostavax
- update the Australian Immunisation Register (AIR) rules for the human papillomavirus (HPV) vaccine, from a 2-dose schedule to a single-dose schedule provided to adolescents through school-based programs.

The Shingrix vaccine will be funded under the NIP for the following cohorts:

- 18 years and over – immunocompromised individuals at high risk of herpes
- 50 years and over – Aboriginal and Torres Strait Islander people
- 70 years – non-Indigenous people.

The measure also expands the cohorts that will be eligible to receive HPV vaccines funded through the NIP. Notifications to the extended cohorts will commence from September 2023. This change is in line with the World Health Organisation's evaluation of the administration of the vaccine.

This measure is led by the Department of Health and Aged Care. Services Australia has been allocated a total of \$5.3 million through to 2026-27 to support this measure.

This measure is not subject to legislation passing.

Who this measure affects

This measure affects people who require a Shingrix vaccination. This measure affects also the adolescents who require HPV and adults who are overdue to receive the vaccination.

When this starts and finishes

This initiative will start on 1 September 2023 and is ongoing.